U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146815) titled 'PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease' on July 29.
Brief Summary: To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
Study Start Date: Nov. 29, 2022
Study Type: INTERVENTIONAL
Condition:
NAFLD (Nonalcoholic Fatty Liver Disease)
Polycystic Ovarian Syndrome (PCOS)
Intervention:
DIAGNOSTIC_TEST: FibroScan
Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
DIAGNOSTIC_TEST: MRI PDFF
Performance of an MRI-PDFF to determine amount of liver ...